Myriad Genetics
Offers hereditary cancer, tumor profiling, prenatal, and GeneSight pharmacogenomic tests.
Something off on this page? Send us feedback.
Profile
Sells molecular diagnostic and precision medicine tests across oncology, women's health, and mental health. Revenue is disclosed by hereditary cancer, tumor profiling, prenatal, and mental health categories while operations are managed as one segment.
Runs a molecular diagnostics and precision medicine test menu anchored in oncology, women's health, and mental health. Current brands include MyRisk, BRACAnalysis CDx, MyChoice CDx, Prolaris, Precise Tumor, Precise MRD, Prequel, Foresight, FirstGene, SneakPeek, and GeneSight.
Extends the original BRCA cancer-risk franchise into tumor profiling, prenatal testing, and pharmacogenomics. Assurex added GeneSight in mental health, while Counsyl added reproductive genetic testing capabilities that support the women's-health portfolio.
Operates from Salt Lake City under one reporting segment. Execution depends on reimbursement coverage, companion-diagnostic approvals, product launches such as Precise MRD, and the broader post-BRCA patent environment.
Company facts
Key statistics
Year to date −48.8% · Average volume (30d) 2.2M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Aug 18, 2026 | Stephens | Target | $22 | $3 | ||
| Aug 3, 2026 | Wells Fargo | Reiterate | Equal Weight | $6 | $3 | |
| Feb 24, 2026 | UBS | Reiterate | Neutral | $8 | $6 | |
| Nov 4, 2025 | UBS | Reiterate | Neutral | $7 | $8 | |
| May 21, 2025 | Scotiabank | Downgrade | Sector Outperform | Sector Perform |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Jul 30, 2026Q2 FY26 | −$0.06 | −$0.25 | −331.9% | $206.0M | $190.7M | −7.4% | −46.74% |
| May 5, 2026Q1 FY26 | −$0.06 | −$0.09 | −50.0% | $202.4M | $200.4M | −1.0% | −18.29% |
| Feb 23, 2026Q4 FY25 | −$0.02 | $0.04 | +300.0% | $207.4M | $209.8M | +1.1% | +1.14% |
| Nov 3, 2025Q3 FY25 | −$0.01 | −$0.13 | −1,200.0% | $207.0M | $205.7M | −0.6% | −21.03% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $195.9M | $213.1M | $205.7M | $209.8M | $200.4M | $190.7M | |
| Gross profit | $134.2M | $151.8M | $143.8M | $146.8M | $137.6M | $127.0M | |
| Operating income | −$29.0M | −$329.2M | −$23.3M | −$5.7M | −$30.7M | −$38.9M | |
| Net income | −$100.0K | −$330.5M | −$27.4M | −$7.9M | −$34.1M | −$43.2M | |
| Diluted EPS | −$0.00 | −$3.57 | −$0.29 | −$0.08 | −$0.36 | −$0.46 | |
| Gross margin | 68.5% | 71.2% | 69.9% | 70.0% | 68.7% | 66.6% | |
| Operating margin | -14.8% | -154.5% | -11.3% | -2.7% | -15.3% | -20.4% |
Fiscal years (4-quarter sums)FY21 $690.6M · FY22 $678.4M · FY23 $753.2M · FY24 $837.6M · FY25 $824.5M
Revenue by geography · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $115.2M · Total debt $210.5M · Total assets $638.9M · Shareholders' equity $303.9M
Dividends
No dividends on record.
Ownership
Institutions and insiders are filed separately and overlap, so together they can pass the whole company. No split is drawn from them.
Shares outstanding 94.45M · Float 87.86M · 93.0% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 10.89M | 11.53% | 13F | Aug 7, 2026 |
| Millennium Management LLC | 6.62M | 7.01% | 13F | Aug 14, 2026 |
| Vestal Point Capital, LP | 5.74M | 6.10% | 13G | Aug 14, 2026 |
| Integrated Core Strategies (US) LLC | 5.18M | 5.60% | 13G | Feb 11, 2026 |
| State Street Corporation | 4.99M | 5.30% | 13G | Aug 7, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jun 8, 2026 | Rashmi Kumar | director | −15,000 | $4.46 |
| May 14, 2026 | Paul Bisaro | director | +7,500 | $3.69 |
| Mar 9, 2026 | Samraat S. Raha | director, officer: President and CEO | +40,000 | $5.00 |
| Feb 25, 2026 | S. Louise Phanstiel | director | +6,100 | $4.74 |
| Feb 26, 2026 | S. Louise Phanstiel | director | +50,407 | $4.80 |
Peers
- Natera
Broad overlap in prenatal, hereditary cancer, and MRD testing
- Tempus AI
Direct overlap in oncology, hereditary cancer, and GeneSight PGx
- Labcorp
Scale lab rival across genetics, oncology, prenatal, and PGx
- BillionToOne
Direct prenatal challenger with growing oncology liquid biopsy
- Quest Diagnostics
National lab rival in advanced diagnostics and genetic testing
- Guardant Health
Precision-oncology rival in tumor profiling, CDx, and MRD
- Caris Life Sciences
Precision-oncology rival in molecular profiling and therapy selection
- Veracyte
Cancer classifier rival centered on prostate genomics
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Myriad Genetics | $3.16 | +0.48% | $298.5M | — | — | 0.4 | −10.5% |
| Natera | $325.30 | −0.26% | $46.73B | — | — | 17.3 | +37.7% |
| Tempus AI | $63.44 | −0.89% | $11.22B | — | — | 7.8 | +21.6% |
| Labcorp | $333.00 | −0.68% | $27.48B | 27.7 | 17.7 | 1.9 | +5.8% |
| BillionToOne | $93.00 | −0.33% | $4.29B | 150.4 | 123.1 | 10.8 | — |
| Quest Diagnostics | $244.50 | +0.69% | $26.79B | 25.8 | 21.2 | 2.3 | +10.2% |
| Guardant Health | $161.50 | −0.03% | $21.67B | — | — | 18.3 | +44.3% |
| Caris Life Sciences | $25.63 | −0.03% | $7.25B | 71.6 | 101.6 | 7.3 | +45.4% |
| Veracyte | $44.20 | +2.01% | $3.46B | 31.0 | 23.9 | 6.2 | +15.5% |
| Median | 31.0 | 23.9 | 7.6 | +21.6% |